Patents by Inventor Zhongxing Zhang

Zhongxing Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS USEFUL AS IMMUNOMODULATORS
    Publication number: 20180057455
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: August 29, 2017
    Publication date: March 1, 2018
    Inventors: KAP-SUN YEUNG, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, David R. Langley, Piyasena Hewawasam, Tao Wang, Zhongxing Zhang, Zhaoxing Meng, Li-Qiang Sun, Eric Mull, Paul Michael Scola
  • BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20180030016
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth.
    Type: Application
    Filed: February 17, 2016
    Publication date: February 1, 2018
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, John F. Kadow
  • Macrocyclic molecules as HCV entry inhibitors
    Patent number: 9868743
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: January 16, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Eric Gillis, Paul Michael Scola
  • SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS
    Publication number: 20180000849
    Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    Type: Application
    Filed: September 14, 2017
    Publication date: January 4, 2018
    Inventors: Yasutsugu UEDA, Timothy P. CONNOLLY, John F. KADOW, Nicholas A. MEANWELL, Tao WANG, Chung-Pin H. CHEN, Kap-Sun YEUNG, Zhongxing ZHANG, David Kenneth LEAHY, Shawn K. PACK, Nachimuthu SOUNDARARAJAN, Pierre SIRARD, Kathia LEVESQUE, Dominique THORAVAL
  • HYDROFLUOROOLEFINS AND METHODS FOR USING SAME
    Publication number: 20170369755
    Abstract: A composition that includes a hydrofluoroolefin represented by the following general formula (I): Rf—CH2CH—CHCH2-Rf (I). Rf is a perfluoroalkyl group having 6 carbon atoms, and the hydrofluoroolefin is a liquid at room temperature.
    Type: Application
    Filed: December 1, 2015
    Publication date: December 28, 2017
    Inventor: Zhongxing Zhang
  • 2-(aryl or heteroaryl-)phenyl (AZA)benzofuran compounds for the treatment of hepatitis C
    Patent number: 9840511
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: formula (I).
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: December 12, 2017
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, John F. Kadow
  • Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
    Patent number: 9834566
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: December 5, 2017
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John F. Kadow, B. Narasimhulu Naidu, Manoj Patel, Kevin Peese, Tao Wang, Zhiwei Yin, Zhongxing Zhang
  • FUROPYRIDINE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20170247385
    Abstract: Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: August 4, 2015
    Publication date: August 31, 2017
    Applicant: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Kyle J. Eastman, Zhongxing Zhang, Kyle E. Parcella, John F. Kadow
  • MACROCYCLIC BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20170217989
    Abstract: Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: October 1, 2015
    Publication date: August 3, 2017
    Inventors: Tao Wang, Zhongxing Zhang, John F. Kadow
  • 6H-FURO[2,3-E]INDOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20170174696
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: March 20, 2015
    Publication date: June 22, 2017
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tao Wang, Zhongxing Zhang, John F. Kadow
  • Guanidine derivatives for the treatment of hepatitis C
    Patent number: 9655902
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: May 23, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Ying Han, Zhiwei Yin, Paul Michael Scola
  • Tricyclic alkene derivatives as HIV attachment inhibitors
    Patent number: 9655888
    Abstract: Compounds of Formula (I), including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: and wherein Z is: are useful as HIV attachment inhibitors.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: May 23, 2017
    Assignee: ViiV Healthcare UK (No.5) Limited
    Inventors: Tao Wang, John F. Kadow, Nicholas A. Meanwell, Zhongxing Zhang, Zhiwei Yin, Edward H. Ruediger, Clint A. James, Daniel H. Deon
  • SUBSTITUTED 2-PHENYL (AZA)BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20170121340
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth.
    Type: Application
    Filed: June 10, 2015
    Publication date: May 4, 2017
    Inventors: Tao WANG, Zhongxing Zhang, Kyle E. Parcella, Kyle J. Eastman, John F. Kadow
  • Macrocyclic compounds as HCV entry inhibitors
    Patent number: 9624245
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: April 18, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Zhiwei Yin, Li-Qiang Sun, Eric Mull, Qian Zhao, Paul Michael Scola
  • Squaric derivatives for the treatment of hepatitis C
    Patent number: 9624180
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: April 18, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Paul Michael Scola
  • 2-(ARYL- OR HETEROARYL-)PHENYL (AZA)BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
    Publication number: 20170101416
    Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: formula (I).
    Type: Application
    Filed: May 19, 2015
    Publication date: April 13, 2017
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tao WANG, Zhongxing Zhang, John F. Kadow
  • 2-keto amide derivatives as HIV attachment inhibitors
    Patent number: 9586957
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: I useful as HIV attachment inhibitors.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: March 7, 2017
    Assignee: ViiV Healthcare UK (No.5) Limited
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, John A. Bender, Barry L. Johnson, John F. Kadow, Nicholas A. Meanwell
  • PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20170057977
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: February 13, 2015
    Publication date: March 2, 2017
    Inventors: John F. KADOW, B. Narasimhulu NAIDU, Manoj PATEL, Kevin PEESE, Tao WANG, Zhiwei YIN, Zhongxing ZHANG
  • SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS
    Publication number: 20160361328
    Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    Type: Application
    Filed: August 29, 2016
    Publication date: December 15, 2016
    Inventors: Yasutsugu UEDA, Timothy P. CONNOLLY, John F. KADOW, Nicholas A. MEANWELL, Tao WANG, Chung-Pin H. CHEN, Kap-Sun YEUNG, Zhongxing ZHANG, David Kenneth LEAHY, Shawn K. PACK, Nachimuthu SOUNDARARAJAN, Pierre SIRARD, Kathia LEVESQUE, Dominique THORAVAL
  • Piperidine amide derivatives as HIV attachment inhibitors
    Patent number: 9505752
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: formula (I): wherein A is selected from the group consisting of: formula (II) and wherein Z is selected from the group consisting of: formula (III): and. are useful as HIV attachment inhibitors.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: November 29, 2016
    Assignee: ViiV Healthcare UK (No. 5) Limited
    Inventors: Tao Wang, Zhongxing Zhang, John F. Kadow, Nicholas A. Meanwell, Edward H. Ruediger, Clint A. James, Daniel H. Deon, David J. Carini, Barry L. Johnson